Related Experiment Videos
Matrix metalloproteinases and atherosclerotic plaque instability
Ian M Loftus1, A R Naylor, P R F Bell
1Department of Surgery, Leicester University, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK. ianloftus@aol.com
The British Journal of Surgery
|May 25, 2002
Summary
Matrix metalloproteinases (MMPs) are implicated in atherosclerotic plaque disruption. Inhibiting MMPs may offer therapeutic benefits for vascular pathology, warranting further in vivo studies.
Area of Science:
- Cardiovascular Research
- Biochemistry
- Pathology
Background:
- Matrix metalloproteinases (MMPs) play a role in atherosclerosis.
- Increased MMP activity is linked to atherosclerotic plaque disruption, a precursor to cardiac events and stroke.
- MMPs are potential therapeutic targets for vascular pathology.
Purpose of the Study:
- To review the role of matrix metalloproteinases in atherosclerosis.
- To assess the evidence for MMP activity in plaque disruption and vascular disease.
- To evaluate the therapeutic potential of MMP inhibition.
Main Methods:
- Literature search of the Medline database.
Main Results:
- Convincing evidence supports increased MMP activity during acute plaque disruption.
- Less evidence exists for an MMP-driven imbalance promoting matrix degradation.
- MMP inhibition in vascular disease models suggests potential therapeutic benefits.
Conclusions:
- In vivo studies are needed to investigate MMP inhibition for reversing or slowing tissue remodeling in plaque disruption.